| Project/Area Number |
25670465
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
MORISHIMA Tsuneo 岡山大学, 医歯(薬)学総合研究科, 特命教授 (90157892)
|
|---|
| Research Collaborator |
FUJI Yousuke 岡山大学, 大学院医歯薬学総合研究科小児急性疾患学講座, 助教 (80549775)
TSUGE Mitsuru 松山赤十字病院, 小児科 (80625004)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | インフルエンザ / 肺炎 / HMGB-1 / チオレドキシン / H5N1 / 脳症 / AH7N9 / ARDS / 喘息 / H1N1pdm |
|---|
| Outline of Final Research Achievements |
The discovery of a novel anti-influenza therapeutic approach would increase the effectiveness of traditional virus-based strategies. This study was undertaken to evaluate the therapeutic effects of anti-high mobility group box-1 (HMGB1) monoclonal antibody (mAb) treatment for influenza A virus (H1N1)-induced pneumonia in mice.Anti-HMGB1 mAb significantly improved the survival rate of H1N1-inoculated mice. The treatment also significantly attenuated histological changes and neutrophil infiltration in the lung of H1N1-inoculated mice; which was associated with inhibition of HMGB1 and suppression of inflammatory cytokine/chemokine expression and oxidative stress enhancement, which were observed in H1N1-inoculated mice. Anti-HMGB1 mAb may provide a novel and effective pharmacological strategy for severe influenza virus infection in humans by reducing the inflammatory responses induced by HMGB1.
|
